DescriptionCurator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2364036 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | BACITRACIN Approved UseUses first aid to help prevent infection in: •minor cuts •scrapes •burns Launch Date1948 |
|||
Curative | CORTISPORIN Approved UseFor the treatment of corticosteroid-responsice dermatoses with secondary infection. Launch Date1957 |
|||
Curative | NEOSPORIN Approved UseNEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. Launch Date1968 |
PubMed
Title | Date | PubMed |
---|---|---|
Bacitracin: Methods of Production, Concentration, and Partial Purification, with a Summary of the Chemical Properties of Crude Bacitracin. | 1948 Feb |
|
The relative antisyphilitic activity of penicillins F,G,K, and X and of bacitracin, based on the amounts required to abort early syphilic infections in rabbits. | 1948 Mar |
|
The Action of Bacitracin and Subtilin on Treponema pallidum in Vitro and in Vivo. | 1948 Mar |
|
The Results of the Systemic Administration of the Antibiotic, Bacitracin, in Surgical Infections: A Preliminary Report. | 1948 Oct |
|
A Note on the Susceptibility of Hemophilus influenzae Type B to Bacitracin. | 1948 Oct |
|
The Use of Bacitracin in Experimental Clostridium Welchii Infection in Guinea Pigs. | 1949 Oct |
|
IN VITRO STUDIES ON POSSIBLE SYNERGISTIC ACTION BETWEEN PENICILLIN AND BACITRACIN. | 1949 Sep |
|
In vitro sensitivity of Bacillus proteus and Pseudomonas aeruginosa to seven antibiotics; penicillin, streptomycin, bacitracin, polymyxin, aerosporin, aureomycin, and chloromycetin. | 1950 Feb |
|
Systemic bacitracin in the treatment of progressive bacterial synergistic gangrene. | 1950 Feb |
|
Cholesterol 7alpha-hydroxylase. 2. Biochemical properties and participation of endogenous cholesterol in the assay in vitro. | 1975 Jun 16 |
|
Continuous administration of growth hormone does not prevent the decrease of IGF-I gene expression in zinc-deprived rats despite normalization of liver GH binding. | 1998 Dec |
|
Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. | 1999 May |
|
Nitric oxide induces Zn2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. | 1999 Nov 15 |
|
Plasma apolipoprotein B-48, hepatic apolipoprotein B mRNA editing and apolipoprotein B mRNA editing catalytic subunit-1 mRNA levels are altered in zinc-deficient rats. | 1999 Oct |
|
Individual variability in the zinc inducibility of metallothionein-IIA mRNA in human lymphocytes. | 2000 Dec 15 |
|
Defective antioxidant defense system in patients with a human leptin gene mutation. | 2000 Jul |
|
Reduction of oxidative stress and cytokine-induced neutrophil chemoattractant (CINC) expression by red wine polyphenols in zinc deficiency induced intestinal damage of rat. | 2000 Jun 1 |
|
Increased protein intake during recovery from zinc deficiency is accompanied by alterations in hypothalamic growth hormone releasing factor and somatostatin. | 2001 |
|
Metallothionein isogene transcription in red blood cell precursors from human cord blood. | 2001 Feb |
|
Arsenite-inducible RNA-associated protein (AIRAP) protects cells from arsenite toxicity. | 2001 Jan |
|
The human ZIP1 transporter mediates zinc uptake in human K562 erythroleukemia cells. | 2001 Jun 22 |
|
[Effect of zinc deficiency and zinc replenishment on HOX3.5 gene expression in mouse embryos]. | 2001 Nov |
|
Modulation of intestinal gene expression by dietary zinc status: effectiveness of cDNA arrays for expression profiling of a single nutrient deficiency. | 2001 Nov 20 |
|
Attenuation of both apoptotic and necrotic actions of cadmium by Bcl-2. | 2002 Jan |
|
S-nitrosothiols react preferentially with zinc thiolate clusters of metallothionein III through transnitrosation. | 2002 Jul 2 |
|
Brain-specific metallothionein-3 has higher metal-binding capacity than ubiquitous metallothioneins and binds metals noncooperatively. | 2002 May 14 |
|
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. | 2002 Nov |
|
Zinc transporters in the rat mammary gland respond to marginal zinc and vitamin A intakes during lactation. | 2002 Nov |
|
Effect of chromium on apolipoprotein A-I expression in HepG2 cells. | 2003 Apr |
|
Changes in rat hepatic gene expression in response to zinc deficiency as assessed by DNA arrays. | 2003 Apr |
|
Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes. | 2003 Feb 15 |
|
A novel class of ligand-gated ion channel is activated by Zn2+. | 2003 Jan 10 |
|
In vitro effect of metal ions on the activity of two amphibian glyceraldehyde-3-phosphate dehydrogenases: potential metal binding sites. | 2003 Jun |
|
Zinc accumulation in N-methyl-N-nitrosourea-induced rat mammary tumors is accompanied by an altered expression of ZnT-1 and metallothionein. | 2003 Jun |
|
Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. | 2003 Mar |
|
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003 May 2 |
|
Regulated cell surface pro-EGF ectodomain shedding is a zinc metalloprotease-dependent process. | 2003 Nov 14 |
|
Thymulin evokes IL-6-C/EBPbeta regenerative repair and TNF-alpha silencing during endotoxin exposure in fetal lung explants. | 2004 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50168slr078_cotisporin_lbl.pdf
Curator's Comment: Bacitracin can be used as ophtalmic solution (0.025mg/ml) for the treatment of superficial ocular infections.
400 units, topically
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
1284
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QR02AB04
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
J01XX10
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 333.120
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 524.155
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
R02AB04
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 556.70
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
EPA PESTICIDE CODE |
6302
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 333.110
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 524.154
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
CFR |
21 CFR 520.154
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-ATC |
D06AX05
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QJ01XX10
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QD06AX05
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
||
|
WHO-VATC |
QA07AA93
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BACITRACIN
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
100000092135
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
215-786-2
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
755905
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
SUB00652MIG
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1291
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
BACITRACIN
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Description: A white or pale brownish yellow powder; odourless or with a faint characteristic odour. Solubility: Freely soluble in water, methanol R and ethanol (~750 g/l) TS; practically insoluble in acetone R and ether R. Category: Antiinfective drug. Storage: Bacitracin should be kept in a tightly closed container, protected from light and stored at a temperature between 2? and8?C. If it is intended for parenteral administration, the container should be sterile and sealed so as to exclude micro-organisms. Labelling: The designation sterile Bacitracin indicates that the substance complies with the additional requirements for sterileBacitracin and may be used for parenteral administration or for other sterile applications. Additional information: Bacitracin is hygroscopic. Its solutions deteriorate rapidly at room temperature. Even in the absence oflight, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. | ||
|
DB00626
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
C295
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1167
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
m2197
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
N0000008479
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | Decreased Cell Wall Synthesis & Repair [PE] | ||
|
Bacitracin
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
58H6RWO52I
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
D001414
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
1405-87-4
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200558
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
281
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY | |||
|
28669
Created by
admin on Wed Apr 02 09:38:17 GMT 2025 , Edited by admin on Wed Apr 02 09:38:17 GMT 2025
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY
SALT/SOLVATE (PARENT)